Patent classifications
A61K31/315
MEANS AND METHODS FOR TREATING COPPER-RELATED DISEASES
The present invention relates to the field of (bio-)medicine, and more particularly to the treatment of copper-related diseases. Novel means and methods for depleting (excess) copper from organs and/or the circulation are provided. Agents with a high copper binding affinity and stabilized forms thereof are provided, as well as a novel treatment regimen. The means and methods of the present invention are particularly useful for treatment of Wilson Disease, but also for treatment of other conditions.
DEVICES AND METHODS FOR THE TREATMENT OF A ZOONOTIC HERPESVIRUS INFECTION
The present disclosure relates to tetrapodal zinc-oxide nanostructures (T-ZONS), microneedle devices, and methods for treating or preventing a zoonotic herpesvirus infection.
DEVICES AND METHODS FOR THE TREATMENT OF A ZOONOTIC HERPESVIRUS INFECTION
The present disclosure relates to tetrapodal zinc-oxide nanostructures (T-ZONS), microneedle devices, and methods for treating or preventing a zoonotic herpesvirus infection.
A SOLID DOSAGE FORM COMPRISING ZINC GLUCONATE AND INOSINE PRANOBEX, A METHOD FOR ITS PREPARATION AND ITS APPLICATIONS
The subject of the invention is a solid dosage form containing zinc gluconate and inosine pranobex and adjuvants characterized in that zinc gluconate is in an amount of 3.11% to 4.51% by mass of the dosage form, inosine pranobex is in an amount of 71.43% by mass of the dosage form, sodium carboxymethyl starch (type A) is in the range from 5% to 14% by weight of the dosage form and sodium lauryl sulfate at a level from 0.7% to 1% by weight of the dosage form and the mannitol content is from 6% to 10.7% by weight of the dosage form, and method of its preparation and its applications.
A SOLID DOSAGE FORM COMPRISING ZINC GLUCONATE AND INOSINE PRANOBEX, A METHOD FOR ITS PREPARATION AND ITS APPLICATIONS
The subject of the invention is a solid dosage form containing zinc gluconate and inosine pranobex and adjuvants characterized in that zinc gluconate is in an amount of 3.11% to 4.51% by mass of the dosage form, inosine pranobex is in an amount of 71.43% by mass of the dosage form, sodium carboxymethyl starch (type A) is in the range from 5% to 14% by weight of the dosage form and sodium lauryl sulfate at a level from 0.7% to 1% by weight of the dosage form and the mannitol content is from 6% to 10.7% by weight of the dosage form, and method of its preparation and its applications.
SYSTEMS AND METHODS FOR PHOTOBIOMODULATION
The present application is directed to systems, devices, and methods for diagnosing, preventing, and treating diseases and disorders through photobiomodulation therapy, either alone or in combination with one or more other therapies. More particularly, the present invention provides photon source devices configured to deliver light to a portion of an organism, which causes a physiological response within that light exposed organism. The invention also provides a system which includes one or more photon source devices and functionality for diagnosing or assessing a disease or disorder, and for monitoring responsiveness of the disease or disorder to treatment with the therapeutic light. Additionally, this application is directed to utilizing the present systems and devices in combination with known adjunctive therapies including devices, services, drugs, biologics, genetics and supplements to produce synergistic optimal therapeutic outcomes.
SYSTEMS AND METHODS FOR PHOTOBIOMODULATION
The present application is directed to systems, devices, and methods for diagnosing, preventing, and treating diseases and disorders through photobiomodulation therapy, either alone or in combination with one or more other therapies. More particularly, the present invention provides photon source devices configured to deliver light to a portion of an organism, which causes a physiological response within that light exposed organism. The invention also provides a system which includes one or more photon source devices and functionality for diagnosing or assessing a disease or disorder, and for monitoring responsiveness of the disease or disorder to treatment with the therapeutic light. Additionally, this application is directed to utilizing the present systems and devices in combination with known adjunctive therapies including devices, services, drugs, biologics, genetics and supplements to produce synergistic optimal therapeutic outcomes.
METHOD FOR ELIMINATING SPECIFIC PATHOGENIC MICROORGANISMS IN THE BODY
The method for eliminating microorganisms, allows to selectively neutralize pathogens. The method includes a first step which includes measuring the frequencies of pathogens within a human body which are at high population present, resulting in further illnesses or symptoms. The different sized pathogens are then applied a resonant frequency band to pre-damage/crack/weaken the hulls of the microorganisms evenly. The method further includes a second step rupturing the damaged hulls of the pathogens or oxidation of the ARN/ADN in case of a virus with a safe dose of an external oxidation product together with internal produced eNOS-expression (ROS/RNS). The external product may include chlorine dioxide in a watery solution of 0.75 ppm, vitamins, minerals and amino acids to start eNOS-expression. The method further includes a third step to deliberately terminating the activated oxidation processes. A fourth step strengthens the immune system by filling depleted levels of vitamins, minerals and amino acids.
METHOD FOR ELIMINATING SPECIFIC PATHOGENIC MICROORGANISMS IN THE BODY
The method for eliminating microorganisms, allows to selectively neutralize pathogens. The method includes a first step which includes measuring the frequencies of pathogens within a human body which are at high population present, resulting in further illnesses or symptoms. The different sized pathogens are then applied a resonant frequency band to pre-damage/crack/weaken the hulls of the microorganisms evenly. The method further includes a second step rupturing the damaged hulls of the pathogens or oxidation of the ARN/ADN in case of a virus with a safe dose of an external oxidation product together with internal produced eNOS-expression (ROS/RNS). The external product may include chlorine dioxide in a watery solution of 0.75 ppm, vitamins, minerals and amino acids to start eNOS-expression. The method further includes a third step to deliberately terminating the activated oxidation processes. A fourth step strengthens the immune system by filling depleted levels of vitamins, minerals and amino acids.
Zinc composition and their use in anti-microbial applications
The invention relates generally to antimicrobial compositions that are non-toxic to mammals and plants, and are highly effective against a broad spectrum of detrimental pathogenic microorganisms. The antimicrobial compositions contain at least one zinc compound that is microbicidal to at least one microorganism. The antimicrobial compositions of the invention can be diluted in suitable proportions into suitable solvents to produce the desired dosages for each individual application. The antimicrobial compositions can be applied by conventional methods, e.g., spraying, soaking, fogging, impregnation, and the like. The compositions can also be used as preservatives. The antimicrobial compositions can also be made as gels or solids in different forms by using techniques available to those skilled in the art.